LEXEO THERAPEUTICS INC (LXEO)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LXEO
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LXEO | Class I Director | 53 | [] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALNY | Chief Commercial Officer | 52 | ["Over 25 years of experience in the global biopharmaceutical industry","Former Senior Vice President and Head of U.S. at Alexion Pharmaceuticals, Inc.","Former President of the North America rare disease unit at Pfizer","B.S. in Finance and Economics from Istanbul University","MBA from Michigan State University"] | [] | 2025 |
Biography sourced from the proxy statement filing.
Tolga Tanguler has served as a member of our board of directors since November 2024. Mr. Tanguler has served as Chief Commercial Officer of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, since January 2021. Mr. Tanguler also served as the Head of U.S. Organization of Alexion Pharmaceuticals, Inc., a biopharmaceutical company, from November 2018 to December 2020 and as President of Pfizer Rare Disease for the North America region from October 2014 to October 2018. Mr. Tanguler holds a B.S. in Finance and Economics from Istanbul University and an MBA from the Michigan State University. Our board of directors believes Mr. Tanguler is qualified to serve on our board of directors because of his experience holding senior leadership positions within commercial-stage biopharmaceutical companies.